These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 37538810)
1. Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP). Herrington WG; Harper C; Staplin N; Haynes R; Emberson J; Reith C; Hooi LS; Levin A; Wanner C; Baigent C; Landray M; Kidney Int Rep; 2023 Aug; 8(8):1489-1495. PubMed ID: 37538810 [TBL] [Abstract][Full Text] [Related]
2. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Baigent C; Landray MJ; Reith C; Emberson J; Wheeler DC; Tomson C; Wanner C; Krane V; Cass A; Craig J; Neal B; Jiang L; Hooi LS; Levin A; Agodoa L; Gaziano M; Kasiske B; Walker R; Massy ZA; Feldt-Rasmussen B; Krairittichai U; Ophascharoensuk V; Fellström B; Holdaas H; Tesar V; Wiecek A; Grobbee D; de Zeeuw D; Grönhagen-Riska C; Dasgupta T; Lewis D; Herrington W; Mafham M; Majoni W; Wallendszus K; Grimm R; Pedersen T; Tobert J; Armitage J; Baxter A; Bray C; Chen Y; Chen Z; Hill M; Knott C; Parish S; Simpson D; Sleight P; Young A; Collins R; Lancet; 2011 Jun; 377(9784):2181-92. PubMed ID: 21663949 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). Mihaylova B; Schlackow I; Herrington W; Lozano-Kühne J; Kent S; Emberson J; Reith C; Haynes R; Cass A; Craig J; Gray A; Collins R; Landray MJ; Baigent C; Am J Kidney Dis; 2016 Apr; 67(4):576-84. PubMed ID: 26597925 [TBL] [Abstract][Full Text] [Related]
4. Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors. Scirica BM; Im K; Murphy SA; Kuder JF; Rodriguez DA; Lopes RD; Green JB; Ruff CT; Sabatine MS Clin Cardiol; 2022 Jul; 45(7):794-801. PubMed ID: 35715946 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial. Harper C; Mafham M; Herrington W; Staplin N; Stevens W; Wallendszus K; Haynes R; Landray MJ; Parish S; Bowman L; Armitage J JAMA Netw Open; 2021 Dec; 4(12):e2139748. PubMed ID: 34962561 [TBL] [Abstract][Full Text] [Related]
6. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031 [TBL] [Abstract][Full Text] [Related]
19. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Clinically Adjudicated Versus Flow-Based Adjudication of Revascularization Events in Randomized Controlled Trials. Wang R; Kawashima H; Hara H; Gao C; Ono M; Takahashi K; Tu S; Soliman O; Garg S; van Geuns RJ; Tao L; Wijns W; Onuma Y; Serruys PW Circ Cardiovasc Qual Outcomes; 2021 Nov; 14(11):e008055. PubMed ID: 34666500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]